Navigation Links
Aegera initiates Phase 1 clinical trial of AEG33773 - A small molecule in development for diabetic neuropathic pain
Date:3/18/2008

MONTREAL, March 18 /PRNewswire/ - Aegera Therapeutics announced today the initiation of a Phase 1, first-in-man, clinical trial for AEG33773, a novel, orally bioavailable small molecule in development for the treatment of painful diabetic neuropathy. The Phase I study will evaluate the safety, tolerability and pharmacokinetic profile of AEG33773 using a randomized, double blind, placebo controlled, single ascending dose design in healthy male volunteers.

Aegera completed a comprehensive pre-clinical development program on AEG33773, culminating in regulatory clearance from Health Canada and treatment of a first patient, in less than 12 months.

"We are extremely excited about the potential for AEG33773 to treat painful diabetic neuropathy and to expand to other pain and neuropathy indications, based on our extensive preclinical experience with this family of compounds in multiple models of pain and neuropathy," commented Dr. Jon Durkin, Vice-President Research and Preclinical Development at Aegera.

"This important milestone was achieved in record time, as the Aegera team has successfully filed regulatory applications for two potential blockbuster compounds, AEG33773 and AEG40826, in the last three months while initiating multiple Phase 2 trials for our lead program AEG35156. Aegera now has four unique programs in clinical development and is poised to deliver significant clinical data over the next 12-18 months" added Dr. Michael J. Berendt, Aegera's President and CEO.

About AEG33773

AEG33773 was developed as an orally bioavailable small molecule compound which provides acute pain relief in preclinical models of neuropathic and inflammatory pain. In addition, AEG33773's unique mechanism of action has demonstrated excellent in vivo activity in models of diabetic neuropathy with respect to its ability to not only prevent, but also to reverse established neuropathies.

About Aegera Therapeutics Inc.

Aegera Therapeutic
'/>"/>

SOURCE AEGERA THERAPEUTICS INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Human Genome Sciences and Aegera Therapeutics Announce Licensing and Collaboration Agreement on Novel Anti-Cancer Drugs
2. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
3. Dawson James Securities Initiates Research Coverage on CryoCor, Inc. (Nasdaq: CRYO) with a Strong Buy Rating and $6.00 Target Price
4. Spectrum Pharmaceuticals Initiates Second Registrational Phase 3 Clinical Trial for EOquin(R) in Patients With Non-Invasive Bladder Cancer
5. XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
6. Nventa Initiates HspE7 Phase 1 Cervical Dysplasia Trial
7. Cytochroma initiates Phase I/II clinical trial of CTAP101 Capsules for vitamin D insufficiency in chronic kidney disease
8. Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity
9. GeneNews initiates patient sample accrual for validation studies of colon cancer blood test
10. Human Genome Sciences Initiates Second Randomized Phase 2 Trial of HGS-ETR1 in Combination With Chemotherapy
11. Conatus Pharmaceuticals Initiates a Phase 2 Clinical Trial for the Treatment of Hepatitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/3/2015)... 3, 2015 ... osoitteessa  http://www.openinnovationinscience.at Wienissä pidettävään ... Science" -jatkokoulutusohjelmaan 22.7.2015 asti.  ... tekemän, kansainvälisiä tutkijoita ja tiedemiehiä ... suurinta haastetta ovat kannustimien puute ...
(Date:7/3/2015)... 2015 Forskere kan ... in Science", som finner sted i ... nett, på  http://www.openinnovationinscience.at , og søknadsperioden varer ... De to største utfordringene innen helsevitenskapen er ... forskningsspørsmål og kompleksiteten av nåværende forskningsresultater, i ...
(Date:7/2/2015)... College of DuPage students Sam Liesman ... real-world experiences while serving biophysics internships at the prestigious ... students will be working as a part of IIT ... IIT. The internship came about from a discussion between ... Kathy Finan , Biology; and Dr. Wereszczynski regarding ...
(Date:7/2/2015)... ... July 02, 2015 , ... In’Tech Medical ... instruments in Orthopedics, announced today the acquisition of Turner Medical, Inc ., ... of surgical instruments to the Spine Industry. The acquisition of Turner Medical ideally ...
Breaking Biology Technology:Maailman ensimmäinen tiedemiesten koulutukseen suunniteltu avoimen innovaation ohjelma käynnistyy 2Maailman ensimmäinen tiedemiesten koulutukseen suunniteltu avoimen innovaation ohjelma käynnistyy 3Lansering av verdens første Open Innovation-program for utdanning av forskere 2Lansering av verdens første Open Innovation-program for utdanning av forskere 3COD Students Participate in Prestigious Summer Internships 2In'Tech Medical Acquires Turner Medical to Become a World Leader in Orthopedic Contract-Manufacturing 2In'Tech Medical Acquires Turner Medical to Become a World Leader in Orthopedic Contract-Manufacturing 3
... Nfocus device development team.PALO ALTO, Calif., April 30 ... today the appointment of accomplished regulatory executive Robert O,Holla ... President of Regulatory Affairs. "Bob O,Holla brings an unmatched ... , having served 18 of his last 30 years ...
... April 30 Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX ... of drugs for the treatment of human viral diseases, today ... 31, 2009. At March 31, 2009, Idenix,s cash, cash equivalents ... , , ...
... Resonant Medical, an innovator in 3D ultrasound image-guided ... Stephen Whisenhunt to the position of Vice President ... the Company,s growing global sales team and manage ... years of radiation oncology industry experience to the ...
Cached Biology Technology:Nfocus Neuromedical Appoints Robert O'Holla to Head Regulatory 2Idenix Pharmaceuticals Reports First Quarter Financial Results 2Idenix Pharmaceuticals Reports First Quarter Financial Results 3Idenix Pharmaceuticals Reports First Quarter Financial Results 4Idenix Pharmaceuticals Reports First Quarter Financial Results 5Idenix Pharmaceuticals Reports First Quarter Financial Results 6Resonant Medical Expands Sales Organization with Appointment of Vice President of Global Sales and Marketing 2
(Date:6/17/2015)... JOSE, Calif. , June 17, 2015 /PRNewswire/ ... in human interface solutions, today announced that Xiaomi, ... adopted the Synaptics ® ClearPad ® ... of display driver integrated circuits (DDICs) for its ... Pro. By leveraging ClearPad for full in-cell display ...
(Date:6/16/2015)... June 16, 2015 Fingerprint Cards has ... sensors in the company,s portfolio from one of its module ... to mainly take place during the third quarter 2015. The ... Asia . Jörgen Lantto, CEO of FPC, ... the   growing interest from smartphone OEMs in integrating touch ...
(Date:6/15/2015)... Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company") a ... announces that its leading payment security technology, the Wocket® smart ... NYC June 18th. Digital Experience! @ NYC is ... to over 300 of the top media covering the sector. ... New York City from 6:00 to ...
Breaking Biology News(10 mins):Synaptics Touchscreen and Display Driver IC Solutions Power Xiaomi's Latest Flagship Smartphones 2Synaptics Touchscreen and Display Driver IC Solutions Power Xiaomi's Latest Flagship Smartphones 3FPC Receives Order for Touch Fingerprint Sensors of 375 MSEK 2Wocket Smart Wallet Exhibiting at Pepcom Digital Experience! @ NYC June 18th 2Wocket Smart Wallet Exhibiting at Pepcom Digital Experience! @ NYC June 18th 3
... University of Minnesota Medical School and Masonic Cancer ... to discover how some proteins may cause the development ... part of R-spondin family normally help activate cell ... have discovered that when two types of R-spondins ...
... This press release is available in French , ... . STOCKHOLM (24 AUGUST 2012) As food ... and the "super drought" in the US, a new study finds ... insecurity and climate risks in sub-Saharan Africa and South Asia. The ...
... might have unraveled some lingering evolutionary questions about group ... that took a unique approach to observing interactions between ... in the journal Science some of the ... such as schools of fish can evolve as a ...
Cached Biology News:U of M researchers: Newly discovered genetic markers could signal colon cancer development 2Farmer-led irrigation schemes could alter food security in sub-Saharan Africa, South Asia 2Farmer-led irrigation schemes could alter food security in sub-Saharan Africa, South Asia 3Farmer-led irrigation schemes could alter food security in sub-Saharan Africa, South Asia 4Video-gaming fish play out the advantages of groups 2Video-gaming fish play out the advantages of groups 3Video-gaming fish play out the advantages of groups 4
Human peripheral blood CD14+ monocytes, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Monocytes, B Cells, NK Cells and Stem Cells...
Yeast tRNA 50 l...
...
...
Biology Products: